skip to Main Content

2nd Annual Pharma 2020: The Future of R&D Summit

26 - 28 March 2019, Berlin

Join the 2nd Annual Pharma 2020: The Future of R&D Summit, meet professionals from the best pharma companies and academia and learn about the new trends in drug discovery, explore the future promise of Artificial Intelligence and Machine Learning, listen to some case studies about innovations in High Throughput Screening, Big Data and precision medicine, targeting the Protein-Protein Interactions, scientific collaborations, and many other topics.

Request Full Programme Register Online

 SUMMIT WILL HOST SPEAKERS FROM THE WORLD’S LEADING COMPANIES

See Sample of Key Note Speakers and Their Case Studies.

Thorsten
THORMANN

Vice President – Research

Sophie
OLLIVIER

Chief Data Officer R&D

Friedrich
RIPPMANN

Director, Global Computational Chemistry & Biology

Alastair
LAWSON

Senior Fellow, Head of Antibody Biology

Hans
WIDMER

Program Director, Industry-Academia Liaison

Johannes
KIRCHMAIR

Associate Professor in Bioinformatics

EXPERIENCE BASED CASE STUDIES

Current achievement and (near-)future promise of AI in drug discovery
While AI currently seems at the top of its hype cycle, it is sometimes overlooked that certain AI techniques already deliver everyday benefit in drug discovery.

Merck

Targeting protein-protein interactions with small molecule drugs
For a decade, monoclonal antibodies have been very successful drug modalities in this space, but new promising small molecule drug candidates arestarting to appear.

LEO Pharma

Machine-Learning Models for Predicting Frequent Hitter Behavior of Small Molecules

Assay interference caused by small molecules continues to pose significant challenges for early drug discovery.

University of Bergen

HOT CONFERENCE TOPICS

Will Be Discussed

  • Challenges in R&D Data Management
  • Current achievement and (near-)future promise of AI in drug discovery
  • Targeting protein-protein interactions with small molecule drugs
  • Machine-Learning Models for Predicting Frequent Hitter Behavior of Small Molecules
  • Industry-Academia Collaborations – Opportunities and things to consider
  • Antibody-enabled small molecule drug discovery
  • Finding a needle in the haystack via High-Throughput screening approach
  • How to overcome the R&D Productivity killers?
  • The challenges and promise of cancer immunotherapy – Next-generation immune therapies

WHAT DELEGATES SAID

About Allan Lloyds Events

FOR MORE INFORMATION REQUEST FULL PROGRAMME

See what keynote speakers will be taking part in the exclusive speaking panel.
Explore what case studies will be discussed by our senior corporate speakers.

YOU MAY BE INTERESTED IN

2nd Annual Pharma 2020: The Future of R&D Summit
TIME IS RUNNING OUT! DON’T RISK MISSING IT

Back To Top